Sandoz Secures European Approval for Ondibta Insulin Glargine Biosimilar, Targeting 66 Million European Diabetes Patients
核心洞察
Sandoz received European Commission approval for Ondibta (搜索) (insulin glargine), a biosimilar to Lantus SoloStar, confirmed to match the reference medicine in safety, quality and efficacy.
The biosimilar is approved for diabetes mellitus (搜索) treatment in adults, adolescents and children aged two years and above, with launch expected by early 2027.
Ondibta (搜索) has potential to expand access to insulin treatment for tens of millions of European patients, addressing a growing diabetes burden affecting 66 million adults in Europe.
Sandoz has secured European Commission approval for Ondibta (搜索) (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar insulin pen, marking a significant milestone in expanding access to diabetes treatment across Europe. The approval, announced on January 14, 2026, covers all indications of the reference medicine and is expected to launch by early 2027.
Clinical Equivalence and Patient Population
Ondibta (搜索) is approved for the treatment of diabetes mellitus (搜索) in adults, adolescents and children aged two years and above. The biosimilar has been confirmed to match Lantus SoloStar in terms of safety, quality and efficacy following a comprehensive review of analytical and clinical data by European regulators.
The approval addresses a substantial medical need, with 66 million adults aged 20-79 living with diabetes in Europe according to the latest estimates. This figure is projected to increase 10% by 2050 to 72 million patients, with related healthcare expenditure approaching $200 billion.
Strategic Partnership and Development
Ondibta (搜索) was developed and registered by Gan & Lee Pharmaceuticals (搜索) under an agreement established with Sandoz in December 2018. The partnership covers biosimilar versions of insulins glargine, lispro and aspart, with Sandoz responsible for commercialization in Europe and other key territories while Gan & Lee handles development, registration, manufacturing and supply.
Claire D'Abreu-Hayling, Chief Scientific Officer at Sandoz, emphasized the significance of the approval: "Diabetes remains one of the fastest-growing global health challenges, placing a significant burden on tens of millions of patients across Europe, their families and healthcare systems. The approval of Ondibta (搜索) marks an important milestone in addressing this need and underscores our commitment to improving patient access to critical, potentially life-changing biologic medicines."
Market Impact and Biosimilar Leadership
The approval is expected to increase competition, improve affordability and enhance access to insulin treatment options for people living with diabetes in Europe. Insulin glargine is a long-acting basal insulin analog administered once daily, featuring a smooth, peakless, predictable concentration with a prolonged duration of action lasting up to 24 hours.
This approval builds on Sandoz's pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. The company currently maintains a leading global portfolio comprising 13 biosimilars and 27 additional assets in various stages of development.
Financial and Strategic Implications
The Ondibta (搜索) approval represents another step toward Sandoz's strategic objective of capitalizing on a projected $320 billion biosimilar market opportunity over the next 10 years, covering US and EU markets from 2026-2035. Biosimilars have become a key driver of Sandoz's overall group sales, contributing significantly to the company's revenue growth.
Sandoz stock has responded positively to the announcement, trading at CHF 60.88, up 2.77%, within its 52-week range of CHF 26.25 to CHF 61.18. The company recorded net sales of $10.4 billion in 2024, with its biosimilars division serving as a major revenue contributor.
The diabetes burden continues to escalate globally, with the condition capable of causing blindness, kidney failure, heart attacks, stroke and lower limb amputation when the pancreas fails to produce sufficient insulin or when the body cannot effectively utilize the insulin it produces.